Morgan Stanley Vitality Portfolio I (MSVDX)

Fund Assets	2.29M
Expense Ratio	0.95%
Min. Investment	$5,000,000
Turnover	n/a
Dividend (ttm)	0.16
Dividend Yield	2.41%
Dividend Growth	n/a
Payout Frequency	Annual
Ex-Dividend Date	Jun 9, 2026

Previous Close	6.54
YTD Return	0.12%
1-Year Return	24.69%
5-Year Return	n/a
52-Week Low	5.19
52-Week High	6.89
Beta (5Y)	n/a
Holdings	33
Inception Date	Dec 31, 2021

About MSVDX

Morgan Stanley Institutional Fund, Inc. Vitality Portfolio Class I is an actively managed mutual fund that targets long-term capital appreciation by investing primarily in U.S.-based healthcare companies. The fund's core strategy is to seek out firms engaged in the discovery, development, production, or distribution of products and services that capitalize on advances in healthcare. Its investment process emphasizes identifying businesses with sustainable competitive advantages, strong research and development capabilities, and robust new product pipelines. Major holdings often include leading pharmaceutical, biotechnology, and healthcare equipment companies. This portfolio adopts a conviction-weighted approach, resulting in a concentrated mix of holdings, with over half of assets typically allocated to its top ten investments. Managed by an experienced team with deep industry expertise, the fund plays a specialized role within the financial market by offering exposure to innovation within the dynamic healthcare sector. Its focus makes it relevant for investors seeking targeted access to healthcare trends and companies driving medical and scientific advancement.

• Category: Health
• Performance Rating: Below Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: MSVDX
• Share Class: Class I
• Index: Russell 3000 TR

Performance

MSVDX had a total return of 24.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.80%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
MSVOX	Class R6	0.90%
MSVEX	Class A	1.30%
MSVMX	Class C	2.05%

Top 10 Holdings

49.09% of assets

Name	Symbol	Weight
argenx SE	ARGX	8.03%
Eli Lilly and Company	LLY	7.79%
Ascendis Pharma A/S	ASND	5.48%
Nektar Therapeutics	NKTR	4.75%
Thermo Fisher Scientific Inc.	TMO	4.28%
Align Technology, Inc.	ALGN	4.18%
Enliven Therapeutics, Inc.	ELVN	3.90%
10x Genomics, Inc.	TXG	3.77%
NewAmsterdam Pharma Company N.V.	NAMS	3.57%
Structure Therapeutics Inc.	GPCR	3.36%

Dividend History

Ex-Dividend	Amount	Pay Date
Jun 9, 2026	$0.05761	Jun 9, 2026
Dec 11, 2025	$0.09989	Dec 11, 2025
Dec 11, 2024	$0.00456	Dec 11, 2024

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Aug 28, 2026

Data Sources Report a data error